Gyre Therapeutics, Inc. ( GYRE) - Key Metrics
GYRE Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0.29 | -$0.11 | -$0.17 | -$0.18 |
| 2026Q1 | $0.25 | -$0.09 | $0.03 | $0.03 |
| 2025Q4 | $0.41 | -$0.02 | -$0.06 | -$0.06 |
| 2025Q3 | $0.34 | $0.04 | $0.05 | $0.04 |
| 2025Q2 | $0.33 | $0.01 | $0.02 | $0.02 |
GYRE Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -13.73 |
| 2026Q1 | 0% | -17.42 |
| 2025Q4 | 0% | -93.39 |
| 2025Q3 | 0% | 46.63 |
| 2025Q2 | 0% | 367.50 |
GYRE
Price: $6.91
52 week price:
Payout Ratio Range:
Earnings Per Share: -0.21 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 708.3 million